Bristol Myers: accelerated colorectal cancer drug approval

(CercleFinance.com) - Bristol Myers Squibb announces that the US FDA has granted accelerated approval for Krazati, in combination with cetuximab, for adults with previously treated KRAS G12C mutated locally advanced or metastatic colorectal cancer.


This approval is based on the results of the phase 1/2 KRYSTAL-1 study, in which this combination showed an objective response rate of 34% in pre-treated patients with this type of cancer.

This is the second FDA approval for Krazati - reinforcing its potential in all tumor types. Continuation of this indication may depend on verification and description of clinical benefit in a confirmatory trial.


Copyright (c) 2024 CercleFinance.com. All rights reserved.